摘要
目的 观察中药内服外熨对肝肾亏虚型膝骨关节炎(KOA)患者炎性致痛因子、Toll样受体4(TLR4)及核因子-κB(NF-κB)水平的影响。方法 将我院收治的86例KOA患者随机分为观察组与对照组各43例,比较两组临床疗效、治疗前后中医症候积分,采用西部安大略麦克马斯特大学骨关节炎指数可视化量表(WOMAC)评估两组膝关节功能,观察两组治疗前后白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)及环氧合酶(COX-2)、TLR4及NF-κB水平,观察两组用药安全性。结果 治疗后,观察组治疗总有效率显著优于对照组(P<0.05);观察组中医症候积分、WOMAC评分、IL-6、TNF-、COX-2、TLR4及NF-B水平水平均优于对照组(P<0.05)。结论 中药内服外熨法能显著改善肝肾亏虚型KOA患者的临床症状、炎症反应及膝关节功能,治疗效果佳。
Objective To observe the effects of oral administration and abdominal ironing of Chinese medicine on levels of inflammatory pain factors,Toll-like receptor 4(TLR4)and nuclear factor-B(NF-κB)in patients with knee osteoarthritis(KOA)of liver-kidney deficiency type.Methods Eighty-six patients with KOA were randonly divided into observation group and control group with 43 cases each.The clinical curative effect and scores of TCM symptoms before and after treatment between the two groups were compared,the knee function in both groups was assessed byWestern OntarioMacMaster University Osteoarthritis Index(WOMAC),the levels of interleukin-6(IL-6),tumor necrosis factor-α(TNF-α),cyclooxygenase(COX-2),TLR4 and NF-κB before and after treatment,and medication safety in both groups were observed.Results After treatment,the total response rate of treatment in observation group was higher than that in control group(P<0.05);TCM syndrome score and WOMAC,IL-6,TNF-α,COX-2,TLR4 and NF-κB levels in observation group were superior to those in control group(P<0.05).Conclusion Oral administration and abdominal ironing of Chinese medicine can significantly improve clinical symptoms,inflammation response and knee function in patients with KOAof liver-kidney deficiency type with good curative effect.
作者
孙丽萍
徐文娟
SUN Li-ping;XU Wen-juan(Jiangyin Hospital Affiliated to Nanjing University of Chinese Medicine,Jiangyin 214400)
出处
《湖北中医药大学学报》
2023年第6期80-82,共3页
Journal of Hubei University of Chinese Medicine
基金
江苏省江阴市社会发展科技示范项目(项目编号:JY0603A020201180021PB)。
关键词
膝骨关节炎
中药内服外熨
炎性致痛因子
Toll样受体4
核转录因子-ΚB
Knee osteoarthritis
Oral and a dministration abdominal ironing of Chinese medicine
Inflammatory pa in factor
TLR4 receptor 4
NF-κB